EP300 and diffuse large B-cell lymphoma: CREBBP and EP300 are associated with DLBCL, and CREBBP/EP300 mutations induce H3K27 deacetylation and activate the NOTCH signaling pathway, which is closely associated with B-cell malignancies [37].